Articles By Rachel Tate, DO
ICYMI: The Biosimilar "Buy In"
29 May 2023
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients. Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.
Read Article
No is a complete sentence
26 April 2023
No is a complete sentence. For context, I am a "yes" person, and I always have been.
Read Article
The Benefits of Networking
12 April 2023
Networking provides the framework for an exchange of ideas and new opportunities that can actually open doors.
Read Article
Rheumatology Workforce: Is it a Women’s Issue?
10 April 2023
I recently sat down with Dr. Daniel Battafarano, chair of the ACR’s Workforce Solutions Committee, to discuss workforce study findings, their impact on the next few years, and proposed interventions to address these issues.
Read Article
The Biosimilar "Buy In"
21 March 2023
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients. Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.
Read Article
Best of 2022: Myths & Misconceptions with Febrile Disorders
23 December 2022
Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs. While labs often support the diagnosis, these conditions are best diagnosed by genetic testing, or by specific criteria (in the absence of a genetic test). The following is a table that lists common misconceptions (myths) and their clarifying explanations.
Read Article
Cancer Screening Recommendations in Idiopathic Inflammatory Myopathy
28 November 2022
Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the International Myositis Assessment and Clinical Studies Group (IMACS) steering committee.
Read Article
TNFi cycling in axSpA: Results from CorEVITAS Registy study
13 November 2022
Data presented at ACR22 shows that cycling through TNFi in axSpA patients with primary lack of efficacy with first line TNFi has limited additional benefit in controlling disease.
Read Article
Are MDA criteria created equal in PsA?
13 November 2022
Minimal Disease Activity criteria are used to evaluate PsA disease activity and response to treatment. Given that a patient only has to meet 5 of the 7 criteria, should the individual components be weighted equally?
Read Article
Are we really treating Psoriatic disease if we only address active disease domains and T2T?
12 November 2022
It’s widely accepted that Psoriatic disease has multi-system, multi-domain potential that can lead to life altering complications if left untreated or undertreated. Rheumatologists have shifted the way we discuss treatment options and disease state expectations with patients. Two #ACR22 abstracts stood out to me regarding the Psoriatic disease patient experience and will, ultimately, add to what I do in clinic.
Read Article